Marc H. Rohman

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.

N8 Medical, Inc. is an American clinical stage biotechnology company that develops anti-fouling medical devices to reduce infections, complications, and mortality. The private company is based in an undisclosed location and has a platform technology called Cerashield™, which is based on ceragenins, a novel compound invented by Professor Paul B. Savage. The technology has been featured in over 90 peer-reviewed journal articles. Marc H. Rohman has been the CEO of the company since 2019.